Dr. Reddy's Reports ₹240 Crore Semaglutide API Impact In Q1 FY27

Market snapshot: Dr. Reddy's Laboratories reported its Q1 FY27 results, showing a ₹240 crore impact related to its semaglutide API, which includes inventory provisions and other associated costs. Despite this headwind, the company registered a 6% year-over-year revenue growth to ₹8,071 crore.

Data Snapshot

• Q1 FY27 revenue reached ₹8,071 crore, representing a 6% year-over-year and 7% quarter-over-quarter growth.
• The company registered a ₹240 crore impact from its semaglutide API, including inventory provisions and other associated costs.
• EBITDA for the quarter stood at ₹1,009 crore with an EBITDA margin of 12.5%, while Profit After Tax attributable to equity shareholders was ₹443 crore.
• Reported Return on Capital Employed (RoCE) stood at 5.3%, which improves to 8% when excluding the semaglutide API impact.

What's Changed

• Revenue grew by 6% YoY and 7% QoQ to ₹8,071 crore, showing resilient core segment momentum despite high-priority API bottlenecks.
• The semaglutide injectable supply pipeline transitioned from an active launch phase to a temporary halt following the discovery of API-related impurities, reducing the FY27 production target from 12 million to 6–7 million pens.
• Reported Return on Capital Employed (RoCE) was compressed to 5.3% due to the one-off write-down, though the underlying business generated an RoCE of 8% when excluding the semaglutide API impact.

Key Takeaways

• The ₹240 crore hit in Q1 FY27 reflects a major operational setback in complex generic manufacturing, stemming from API-related quality impurities disclosed in July 2026.
• Despite the semaglutide disruption, Dr. Reddy's registered stable top-line growth with a 6% YoY revenue increase to ₹8,071 crore, led by US launches such as Bosutinib.
• The company's EBITDA margins contracted to 12.5% as increased solvent, freight costs from Middle East tensions, and the semaglutide write-down weighed on operating performance.
• The supply halt has forced the company to cut its FY27 semaglutide delivery target from 12 million pens to 6–7 million pens, pushing resumption to late October or early November 2026.

SAHI Perspective

The quality bottleneck in Dr. Reddy's semaglutide API is a reminder of the steep execution hurdles involved in complex peptide manufacturing. While the ₹240 crore provision has severely compressed Q1 margins, the management's early transparency in adjusting FY27 supply targets to 6–7 million pens protects commercial credibility. With a strong cash surplus of ₹3,058 crore, the company has ample capital to implement technical remediation without derailing its broader goal of a 20%+ EBITDA margin by late FY27.

Market Implications

The temporary semaglutide delay may temporarily slow Dr. Reddy's first-mover advantage in highly lucrative generic GLP-1 markets like Canada and India. However, the launch of Bosutinib with 180-day exclusivity in the US will act as a critical revenue buffer, mitigating base erosion from cancer drug Revlimid. In the medium term, revalidating the production process is paramount to restore investor confidence and capture the estimated $100 billion global GLP-1 market.

Trading Signals

Market Bias: Bearish

Operational margins are under pressure following a ₹240 crore semaglutide API inventory hit in Q1 FY27. Profitability is further weighed down by freight and solvent inflation, though top-line growth remains steady.

Overweight: Specialty Pharma, CDMO

Underweight: Large-Cap Generics, GLP-1 Exporters

Trigger Factors:

• Resolution and validation of the semaglutide API manufacturing process by late October 2026.
• Pace of US sales ramp-up for Bosutinib under its 180-day exclusivity window.
• Stabilization of global freight and raw material costs.

Time Horizon: Near-term (0-3 months)

Industry Context

Following the patent expiration of key GLP-1 molecules like Novo Nordisk's Ozempic, Indian drugmakers have raced to enter the global generic market. However, manufacturing complex injectable pens and maintaining API stability has proven to be a high technical barrier. This supply disruption highlights the execution risk inherent in complex generic scale-ups, presenting a tactical window for domestic peers like Sun Pharma and Zydus Lifesciences to capture market share.

Key Risks to Watch

• Further delays in the validation and resumption of the semaglutide API supply past the late October timeline.
• Continued price erosion in the base US generics portfolio as competition intensifies.
• Prolonged escalation of Middle East conflict driving up shipping freight and chemical solvent costs.

Recent Developments

On July 9, 2026, Dr. Reddy's announced a temporary suspension of commercial semaglutide injectable supplies due to an API impurity detected during scale-up, which halved its FY27 pen target to 6–7 million pens. Earlier, in May 2026, the company launched its oral semaglutide brand 'Obeda' in India and debuted its generic semaglutide injection in Canada.

Closing Insight

While the ₹240 crore Q1 headwind is a clear operational bump, Dr. Reddy's underlying portfolio robustness and strong cash position of ₹3,058 crore ensure the long-term investment thesis remains intact once API remediation is complete.

High Performance Trading with SAHI.